Latest Advances in Lung Cancer Research

The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

This article reviews strategies for managing treatment resistance in advanced EGFR-mutated lung cancer, focusing on personalization, parsimony, and partnership.

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.

A groundbreaking study has revealed that a new lung cancer pill significantly cuts the risk of death by 50%.

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

Mirati’s new lung cancer drug Krazati, targeting KRAS mutations, secures FDA approval, offering hope for advanced NSCLC patients.

Mirati’s adagrasib and Keytruda show promise for KRAS G12C-mutated NSCLC with a 49% tumor shrinkage in trials.

AstraZeneca and Daiichi Sankyo’s Enhertu scored an accelerated FDA approval in patients with HER2-mutant NSCLC.

The FDA has granted an orphan drug designation to THIO for the treatment of patients with small cell lung cancer.